Life Sciences
- Overview
- Who To Contact
- Representative Matters
- Recent Developments
Our lawyers and patent agents understand the intersection of science and business. We use that knowledge to help our clients capitalize on innovations and advances in science and technology to grow their businesses. Whether you are a startup driving innovation, a growth-stage company seeking capital or an established player guiding the future of the industry, Aird & Berlis can provide the comprehensive legal services you need to succeed in the life sciences sector.
We provide targeted, scalable Canadian legal advice on the issues facing life sciences businesses, including regulatory, M&A, financing, capital markets, licencing, commercial agreements, intellectual property, labour and employment, privacy, litigation and dispute resolution and tax counsel. The knowledge and experience of the members of our Life Sciences Group ensures a deep understanding of the legal considerations unique to clients operating in this space. Many of our intellectual property professionals and patent and trademark agents hold a PhD, MSc or BEng degree in relevant fields of study, including pharmacology, chemistry and medical sciences, infection and immunity.
Aird & Berlis represents a variety of life science, pharmaceutical, health science, veterinary, agricultural, food and beverage, technology and biotechnology companies, as well as medical device manufacturers, hospitals, universities and research institutions. We act for early-stage, emerging and mature businesses.
Our extensive capital markets expertise helps clients take their business to the next level by assisting with financing and go-public transactions, including initial public offerings, reverse takeovers and qualifying transactions, as well as resulting listings on the Canadian Securities Exchange, TSX, TSXV and NEO Exchange.
Aird & Berlis has the domestic and cross-border legal and regulatory expertise to advise companies, investors, lenders and other market participants who are pursuing opportunities in this space, including in the following specialized areas:
Psychedelics – Aird & Berlis is a recognized leader in the psychedelics industry. We advise private and public psychedelics companies, including companies with a focus on pharmaceutical developments, nutraceutical products and clinics. The legal, regulatory and investment landscape of the psychedelics industry continues to rapidly evolve in Canada, the United States and around the world. Aird & Berlis is at the forefront of this change, just as we were with Canada’s cannabis industry. We advise clients on the complex international and Canadian domestic regulations associated with psychedelics, including compliance with the Controlled Drugs and Substances Act, Criminal Code, Health Canada Act and the Food and Drugs Act. As a full-service law firm, we can draw on the expertise of professionals across all our practice areas to serve the entire suite of legal and patent needs of our psychedelics clients.
Pharmaceuticals – Our team is dedicated to helping clients succeed in Canada’s highly regulated, rapidly evolving pharmaceutical sector. We act for pharmaceutical developers, hospitals, universities, research institutions and Fortune 100 pharmaceutical companies. Our lawyers and patent agents have extensive experience advising on pharmaceutical patent litigation, including infringement and validity actions, as well as proceedings under the Patented Medicines (Notice of Compliance) Regulations.
Medical Devices – We support medical device companies throughout each stage of the product lifecycle. Our lawyers and patent agents support inventors, manufacturers, developers, licensors, distributors, hospitals, investors and other stakeholders. Our work covers diagnostic devices, targeted drug delivery, surgical instruments, assays, wound dressings and prosthetics. We regularly provide support with respect to Health Canada product regulations and licencing requirements in connection with the manufacturing of medical devices.
Food and Beverage Products – Aird & Berlis has experience advising food and beverage companies on all aspects of their businesses. We advise on regulatory compliance, including with respect to food safety legislation, such as the Canadian Food and Drugs Act, and dealing with the Canadian Food Inspection Agency from the perspective of imports and exports, as well as licences, inspections and product recalls.
Other notable areas of our life sciences expertise include agriculture, biology, biotechnology, chemistry, diagnostics, genomics, green technologies, immunology, nanotechnology, therapeutics, veterinary and virology.
Contacts
-
BioFull bio
Sherri earns the trust of her clients by adeptly managing complex and time-sensitive corporate finance transactions and by providing relevant, busines...
-
BioFull bio
Richard is a creative and results-driven corporate finance lawyer. Both domestically and internationally, Richard brings his business knowledge to th...
-
BioFull bio
With extensive experience in a broad range of corporate finance and commercial matters, Jeffrey offers clients a practical and business-minded approac...
Group Members
Representative Matters
-
Willow Biosciences Completes Brokered Private Placement
Aird & Berlis represented Independent Trading Group (ITG) Inc., as lead agent and sole bookrunner, in Willow Biosciences Inc.’s brokered private placement of units. -
Cybin Completes US$150-Million Private Placement of Common Shares
On March 19, 2024, Cybin Inc. completed a US$150-million private placement of common shares. -
Phillips Foods Acquires Assets of Canadian Seafood Processor and Distributor
On March 7, 2024, Phillips Foods Inc., a U.S.-based global processor and distributor of branded seafood products, announced that it will acquire the assets of South Shore Seafoods Group of Companies, ... -
Cybin Announces Completion of Underwritten Public Offering of Units
On November 14, 2023, Cybin Inc. (NEO:CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedel... -
CanAm Scientific Partnership With Dubai Hospital Set to Transform Men’s Health in the UAE
CanAm Scientific, a global leader in technology, supply and manufacturing, has signed an exclusive agreement with Clemenceau Medical Center Hospital in Dubai to establish the hospital as the first med... -
Cybin Inc. Completes Acquisition of Small Pharma Inc.
On October 23, 2023, Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) and Small Pharma Inc. (TSXV: DMT) announced the completion of Cybin's acquisition of all of Small Pharma's issued and outstanding secu... -
Cybin Announces At-the-Market Equity Program of Up to US$35 Million
On August 23, 2023, Cybin Inc. announced the renewal of its previously established at-the-market equity program that allows Cybin to issue and sell up to US$35 million of common shares from treasury t... -
Cybin Completes Overnight Marketed Public Offering of Units
On August 4, 2023, Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) announced the closing of its previously announced overnight marketed public offering. -
Cybin Enters US$30-Million Common Share Purchase Agreement
On May 30, 2023, Cybin Inc. entered into a common share purchase agreement with Lincoln Park Capital Fund, LLC, an institutional investor. -
Juno Pharmaceuticals Acquires Omega Laboratories
Juno Pharmaceuticals Corp., a leader in the commercialization of specialty pharmaceutical products, announced its acquisition of Omega Laboratories.
Recent Developments
-
TheSpotlight
PMPRB’s Jurisdiction Limited to Patented Medicines
This article discusses the Federal Court of Appeal's decision in Galderma Canada Inc v. Canada (Attorney General), which clarified that the Patented Medicine Prices Review Board's jurisdiction is limi... -
Article
B.C. Cost Recovery Legislation Has Significant Implications for Product and Service Providers
The Government of British Columbia has announced its intention to facilitate civil suits by provincial and federal governments seeking cost recovery, on an unprecedented scale, for “health-related wro... -
TheSpotlight
Abuse of Process: Federal Court of Appeal Clarifies Application in PM(NOC) Proceedings
In the recent decision of Janssen Inc. v. Apotex Inc., the Canadian Federal Court of Appeal declared a subsequent action brought under the Patented Medicines (Notice of Compliance) Regulations to be a... -
Firm News
Aird & Berlis Lawyers Recognized in Global Top 200 Psychedelic Lawyers Directory 2024
The following members of our Life Sciences Group were recognized: Sherri Altshuler, Melanie Cole, Sean Green, Danny Kharazmi, Richard Kimel, Jeffrey Merk and Russell Sanders. -
Firm News
Aird & Berlis Welcomes Nine New Partners
Aird & Berlis is pleased to announce that Meaghan Barrett, Jacob Brown, Holly Cunliffe, Alex Kagan, Amy Marcen-Gaudaur, Dasha Peregoudova, Stefan Radovanovich, Russell Sanders and Leah Silber have bec... -
Event
Psychedelics: A Complex and Changing Regulatory Landscape Focused on Scientific Research and IP Protection
- 04:00 PMJoin our panel of industry experts for a complimentary webinar to learn about recent scientific research on psychedelic medicine, updates to the shifting regulatory landscape, and how to navigate the ... -
TheSpotlight
Whose Liability Is It Anyway? The Court Clarifies the Burden in Summary Trials and Infers Inducement
In Janssen Inc. v. Pharmascience Inc., 2022 FC 62, the Federal Court highlighted two important issues: the burden in summary trial proceedings and the evidentiary burden for proving inducement of pate... -
Article
New Tier, New Horizons for the Canadian Securities Exchange
In order to continue to evolve with developments in the Canadian capital markets, particularly with many more established companies choosing the CSE as their preferred Canadian stock exchange, the CSE...